Log in | Register

Biomarker-guided antifungal therapy in patients with suspected invasive candidiasis: Ready for prime time?

José-Artur Paiva| Pierre-Emmanuel Charles
Editorial
Volume 43, Issue 12 / December , 2017

Pages 1889 - 1891

No abstract available.

References

  1. Vincent JL, Rello J, Marshall J, Silva E, Anzueto A, Martin CD, Moreno R, Lipman J, Gomersall C, Sakr Y, Reinhart K (2009) International study of the prevalence and outcomes of infection in intensive care units. JAMA 302:2323–2329
    • View reference on publisher's website
    • View reference on PubMed
  2. Paiva JA, Pereira JM, Tabah A, Mikstacki A, de Carvalho FB, Koulenti D, Ruckly S, Cakar N, Misset B, Dimopoulos G, Antonelli M, Rello J, Ma X, Tamowicz B, Timsit JF (2016) Characteristics and risk factors for 28-day mortality of hospital acquired fungemias in ICUs: data from the EUROBACT study. Crit Care 20:53
    • View reference on publisher's website
    • View reference on PubMed
  3. Bassetti M, Garnacho-Montero J, Calandra T, Kullberg B, Dimopoulos G, Azoulay E, Chakrabarti A, Kett D, Leon C, Ostrosky-Zeichner L, Sanguinetti M, Timsit JF, Richardson MD, Shorr A, Cornely OA (2017) Intensive care medicine research agenda on invasive fungal infection in critically ill patients. Intensive Care Med. https://doi.org/10.1007/s00134-017-4731-2
  4. Kollef M, Micek S, Hampton N, Doherty JA, Kumar A (2012) Septic shock attributed to Candida infection: importance of empiric therapy and source control. Clin Infect Dis 54:1739–1746
    • View reference on publisher's website
    • View reference on PubMed
  5. Ferreira D, Grenouillet F, Blasco G, Samain E, Henon T, Dussaucy A, Millon L, Mercier M, Pili-Floury S (2015) Outcomes associated with routine systemic antifungal therapy in critically ill patients with Candida colonization. Intensive Care Med 41:1077–1088
  6. Pappas PG, Kauffman CA, Andes DR, Clancy CJ, Marr KA, Ostrosky-Zeichner L, Reboli AC, Schuster MG, Vazquez JA, Walsh TJ, Zaoutis TE, Sobel JD (2016) Clinical practice guideline for the management of Candidiasis: 2016 update by the Infectious Diseases Society of America. Clin Infect Dis 62:e1–e50
    • View reference on publisher's website
    • View reference on PubMed
  7. Leroy O, Bailly S, Gangneux JP, Mira JP, Devos P et al (2016) Systemic antifungal therapy for proven or suspected invasive candidiasis: the AmarCAND 2 study. Ann Intensive Care 6:2
    • View reference on publisher's website
    • View reference on PubMed
  8. Timsit JF, Azoulay E, Schwebel C, Charles PE, Cornet M et al (2016) Empirical Micafungin treatment and survival without invasive fungal infection in adults with ICU-acquired sepsis, Candida colonization, and multiple organ failure: the EMPIRICUS Randomized Clinical Trial. JAMA 316:1555–1564
    • View reference on publisher's website
    • View reference on PubMed
  9. Vallabhaneni S, Cleveland AA, Farley MM, Harrison LH, Schaffner W, Beldavs ZG, Derado G, Pham CD, Lockhart SR, Smith RM, (2015). Epidemiology and risk factors for echinocandin nonsusceptible Candida glabrata bloodstream infections: data from a large multisite population-based Candidemia surveillance program, 2008–2014. Open Forum Infect Dis 2: ofv163
  10. Jensen RH, Johansen HK, Søes LM, Lemming LE et al (2016) Posttreatment antifungal resistance among colonizing Candida isolates in Candidemia patients: results from a Systematic Multicenter Study. Antimicrob Agents Chemoth 60:1500–1508
    • View reference on publisher's website
  11. Bailly S, Leroy O, Montravers P, Constantin JM, Dupont H et al (2015) Antifungal de-escalation was not associated with adverse outcome in critically ill patients treated for invasive candidiasis: post hoc analyses of the AmarCAND2 study data. Intensive Care Med 41:1931–1940
  12. de Jong E, van Oers JA, Beishuizen A, Vos P, Vermeijden WJ, Haas LE, Loef BG, Dormans T, van Melsen GC, Kluiters YC, Kemperman H, van den Elsen MJ, Schouten JA, Streefkerk JO, Krabbe HG, Kieft H, Kluge GH, van Dam VC, van Pelt J, Bormans L, Otten MB, Reidinga AC, Endeman H, Twisk JW, van de Garde EMW, de Smet AMGA, Kesecioglu J, Girbes AR, Nijsten MW, de Lange DW (2016) Efficacy and safety of procalcitonin guidance in reducing the duration of antibiotic treatment in critically ill patients: a randomised, controlled, open-label trial. Lancet Infect Dis 16(7):819–827
    • View reference on publisher's website
    • View reference on PubMed
  13. Rhodes A, Evans LE, Alhazzani W, Levy MM, Antonelli M, Ferrer R, Kumar A, Sevransky JE, Sprung CL, Nunnally ME, Rochwerg B, Rubenfeld GD, Angus DC, Annane D, Beale RJ, Bellinghan GJ, Bernard GR, Chiche JD, Coopersmith C, De Backer DP, French CJ, Fujishima S, Gerlach H, Hidalgo JL, Hollenberg SM, Jones AE, Karnad DR, Kleinpell RM, Koh Y, Lisboa TC, Machado FR, Marini JJ, Marshall JC, Mazuski JE, McIntyre LA, McLean AS, Mehta S, Moreno RP, Myburgh J, Navalesi P, Nishida O, Osborn TM, Perner A, Plunkett CM, Ranieri M, Schorr CA, Seckel MA, Seymour CW, Shieh L, Shukri KA, Simpson SQ, Singer M, Thompson BT, Townsend SR, Van der Poll T, Vincent JL, Wiersinga WJ, Zimmerman JL, Dellinger RP (2017) Surviving sepsis Campaign: international Guidelines for management of sepsis and septic shock: 2016. Intensive Care Med 43:304–377
  14. Charles PE, Kus E, Aho S, Prin S, Doise JM, Olsson NO, Blettery B, Quenot JP (2009) Serum procalcitonin for the early recognition of nosocomial infection in the critically ill patients: a preliminary report. BMC Infect Dis 9:49
    • View reference on publisher's website
    • View reference on PubMed
  15. Ostrosky-Zeichner L, Shoham S, Vazquez J, Reboli A, Betts R, Barron MA, Schuster M, Judson MA, Revankar SG, Caeiro JP, Mangino JE, Mushatt D, Bedimo R, Freifeld A, Nguyen MH, Kauffman CA, Dismukes WE, Westfall AO, Deerman JB, Wood C, Sobel JD, Pappas PG (2014) MSG-01: a randomized, double-blind, placebo-controlled trial of caspofungin prophylaxis followed by preemptive therapy for invasive candidiasis in high-risk adults in the critical care setting. Clin Infect Dis 58:1219–1226
    • View reference on publisher's website
    • View reference on PubMed
  16. Nucci M, Nouer SA, Esteves P, Guimaraes T, Breda G, de Miranda BG, Queiroz-Telles F, Colombo AL (2016) Discontinuation of empirical antifungal therapy in ICU patients using 1,3-beta-d-glucan. J Antimicrob Chemother 71:2628–2633
    • View reference on publisher's website
    • View reference on PubMed
  17. Rouzé A, Loridant S, Poissy J, Dervaux B, Sendid B, Cornu M, Nseir S, S-TAFE study group (2017) Biomarker-based strategy for early discontinuation of empirical antifungal treatment in critically ill patients: a randomized controlled trial. Intensive Care Med 43:1668–1677. https://doi.org/10.1007/s00134-017-4932-8

Sign In

Connect with ICM

Top 5 Articles Editors Picks Supplement